Chemoprotectant for gastric toxicity
OwnerEdward A. Neuwelt, Leslie Muldooninventors
Life of this patent
Estimating the term…
Abstract
There is disclosed a method and pharmaceutical composition for treating or mitigating the side effects of cytotoxic cancer therapy for carcinoma-type cancers tumors including administering a thiol-based chemoproctectant agent and administering a cytotoxic agent having a targeting means to the Lewis Y glycoproteins.
Claims34
A method for treating or mitigating the side effects of a cytotoxic cancer therapy for carcinoma type cancers comprising:
- administering at least a cytotoxic agent and a thiol-based chemoprotectant agent intra-arterially, wherein the intra-arterial administration is through a catheter placed into an artery that provides blood flow to an organ most susceptible to toxic side effects of the cytotoxic agent.
A pharmaceutical composition for treatment of carcinoma type cancers for administration via arterial catheter comprising:
- a first agent that is a cancer cytotoxic agent, and a second agent administered intra-arterially, wherein the first agent is a cytotoxic compound that is used for cancer chemotherapy but is dose-limited due to side effects, and the second agent is a thiol-based chemoprotectant agent.
A pharmaceutical composition for mitigating the gastrointestinal side effects from treatment of carcinoma type cancers with agents that bind to the Lewis Y antigen, administered alone, in combination with other cytotoxic agents, or conjugated to other cytotoxic agents, for administration via arterial catheter comprising:
- an agent administered intra-arterially, wherein the agent is a thiol-based chemoprotectant agent.
Dependencies are inferred from the claim text.